A Pharmacokinetic Study Comparing SCT400 And Rituximab in Patients With B-cell Non-Hodgkin's Lymphoma
Status:
Unknown status
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
The primary objective of the study is to assess the pharmacokinetic (PK) similarity of SCT400
versus rituximab (MabThera®) in patients with CD20+ B-cell Non-Hodgkin's Lymphoma.
The secondary objective of the study is to evaluate the pharmacodynamics (PD) and safety of
SCT400 versus rituximab (MabThera®), as well as the presence of human anti-chimeric
antibodies (HACA).